Brayton Purcell LLP

Call For A Free Consultation
800-598-0314

Call For A Free Consultation 800-598-0314

Brayton Purcell LLP
  • Home
  • Firm Overview
    • Our Beliefs
      • Giving Back
      • Our Associations And Memberships
      • The Right To Trial By Jury
    • Regions Served
    • Careers
    • Our Employees Pets
    • Press Releases
  • Attorneys
  • Practice Areas
    • Mesothelioma/Asbestos
    • Personal Injury/Wrongful Death
    • Toxic Substances
    • Estate Planning
    • Other Areas Of Practice
  • Court Successes
    • Trial Verdicts
    • Appeals
  • Testimonials
  • Blog
  • Videos
  • Contact
  • Home
  • Firm Overview
    • Our Beliefs
      • Giving Back
      • Our Associations And Memberships
      • The Right To Trial By Jury
    • Regions Served
    • Careers
    • Our Employees Pets
    • Press Releases
  • Attorneys
  • Practice Areas
    • Mesothelioma/Asbestos
    • Personal Injury/Wrongful Death
    • Toxic Substances
    • Estate Planning
    • Other Areas Of Practice
  • Court Successes
    • Trial Verdicts
    • Appeals
  • Testimonials
  • Blog
  • Videos
  • Contact

T-cell therapy shows promise for cancer patients

by Brayton Purcell LLP | Aug 17, 2020 | Mesothelioma

microscope looking at a slide

An emerging treatment for mesothelioma is showing significant progress for reducing tumors. Immunotherapy company TCR2 Therapeutics announced the positive results in a press release on July 26.

The company says the first five patients in the clinical trial showed tumor regression within the first six months. According to the study, tumors shrank by an average of 42%.

First phase of clinical trial brings hope

TCR2 Therapeutics says all patients received the same dose of TC-210 TRuC-T cell products, and only one patient experienced difficulties with the therapy. The company’s CEO says the early results are encouraging but adds the trial is still in the early stages. The process consists of three phases:

  • Phase I: Determine the efficacy and safety of the treatment before increasing dosages in cancer patients.
  • Phase II: The trial will expand to 50 patients using the dosage data from the first phase and monitor how effective the treatment is for tumor control and regression.
  • Phase III: The company will seek approval from the Food and Drug Administration after establishing a treatment plan.

Patients in Phase II will have a diagnosis of malignant pleural/peritoneal mesothelioma, non-small lung cancer, ovarian cancer or cholangiocarcinoma and their doses will be managed accordingly.

Treatment offers hope for late-stage cancer patients

While the data is incomplete, TCR2 Therapeutics Chief Medical Officer Alfonso Quintas-Cardama says the therapy brings hope, especially for patients who have not achieved results from other forms of treatment.

The company is still recruiting patients for the trial, and people can sign up for the first phase. TRuC-T cells would add another treatment along with chimeric antigen receptor therapy for mesothelioma, which typically has a poor prognosis.

Recent Posts

  • Boiler Room Workers and Asbestos Exposure
  • Mitigating the financial impact of mesothelioma treatments
  • The EPA’s difficulty with data disclosure
  • Judge orders EPA to close loopholes on asbestos-related reporting
  • Department of Veterans Affairs Increases Pension Rate for 2021

Archives

Categories

RSS Feed

Subscribe To This Blog’s Feed

Free Consultation

Take The First Step In Resolving Your Issue. Send Us An Email.

Email Us For A Response

San Francisco
Bay Area Office

222 Rush Landing Road Novato, CA 94945

Novato Office
222 Rush Landing Road
Novato, CA 94945
Toll Free: 800-598-0314
Phone: 415-898-1555
Fax: 415-898-1247

Map & Directions

Southern California
Office

12 28th Street Venice, California 90291

Los Angeles Office
12 28th Street
Venice, California 90291
Toll Free: 800-598-0314
Phone: 415-898-1555
Fax: 415-898-1247

Map & Directions
  • Follow
  • Follow
  • Follow
  • Follow
  • Follow

© 2021 Brayton Purcell LLP. All Rights Reserved.

Disclaimer | Site Map | Privacy Policy | Business Development Solutions by FindLaw, part of Thomson Reuters

Review Us